Showing 3181-3190 of 3844 results for "".
- In With the Old: Curettage and Cryosurgery Still Effective for BCChttps://practicaldermatology.com/news/in-with-the-old-curettage-and-cryosurgery-still-effective-for-bcc/2461815/The combination of curettage and cryosurgery is a safe and effective treatment method for basal cell carcinoma, and now, a new study presents the results from testing different variants of the method. The current study, which appears in the Journal of the American Academy of Dermat
- Dr. Neil Shah Named New KOL for LASEROPTEK Co. Ltd.https://practicaldermatology.com/news/dr-neil-shah-named-new-kol-for-laseroptek-co-ltd/2461797/Neil Shah, MD, is now a national key opinion leader (KOL) for LASEROPTEK's PALLAS UVB laser system for inflammatory skin conditions. LASEROPTEK's PALLAS laser system is a UVB laser that is US Food and Drug Administration (FDA) -cleared to treat inflammatory skin condit
- Breaking Business News: Lilly to Acquire DICE Therapeuticshttps://practicaldermatology.com/news/breaking-business-news-lilly-to-acquire-dice-therapeutics/2461796/Eli Lilly and Company will acquire DICE Therapeutics, Inc. for a cool $2.4 billion to expand its immunology pipeline. DICE Therapeutics, Inc. is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic c
- Health Canada Greenlights Sun Pharma’s Winlevi for Acnehttps://practicaldermatology.com/news/health-canada-greenlights-sun-pharmas-winlevi-for-acne/2461792/Health Canada has given its nod to Sun Pharma’s Winlevi (clascoterone cream 1%). Winlevi an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. It will be available in Canada this Fall. "
- Dermwire Chats with HS Docuseries Host Jasmine Ivanna Espyhttps://practicaldermatology.com/news/directors-cut-dermwire-chats-with-hs-docuseries-director-jasmine-ivanna-espy/2461776/Thanks to a burgeoning pipeline of potential new treatments and new education and awareness efforts, hidradenitis suppurativa (HS) is finally getting the attention that it deserves. Novartis recently premiered a new docuseries on life with HS at the 2023 Tribeca Film Fest
- New RNA Monitoring Method May Allow for Early Diagnosis of AD in Infantshttps://practicaldermatology.com/news/new-rna-monitoring-method-may-allow-for-early-diagnosis-of-ad-in-infants/2461771/A novel monitoring method that enables human skin transcriptome analysis of the mRNA in sebum) collected from the skin using a simple oil-blotting film may help diagnose atopic dermatitis earlier than is currently possible. According to a newstudy
- News You Can Use: SID Announces New Research Grant Program Focusing on Type 2 Inflammationhttps://practicaldermatology.com/news/news-you-can-use-sid-announces-new-research-grant-program-focusing-on-type-2-inflammation/2461767/The Society for Investigative Dermatology’s (SID) new research grant program, The SID Type 2 Inflammation Innovation Awards, is open now and the deadline is August 31, 2023
- Biosimilar Update: Dr. Reddy’s Completes Phase I Study of Proposed Tocilizumab Biosimilarhttps://practicaldermatology.com/news/biosimilar-update-dr-reddys-completes-phase-i-study-of-proposed-tocilizumab-biosimilar/2461765/Dr. Reddy’s Laboratories’ tocilizumab biosimilar candidate, DRL_TC, met its primary and secondary endpoints in a Phase I study. The company is now initiating a global Phase III study with the aim of comparing the efficacy, safety, tolerability and immunogeni
- Melanoma Metastasis Discovery: Skin Cancer Rewires Energy Systems to Spreadhttps://practicaldermatology.com/news/melanoma-metastasis-discovery-skin-cancer-rewires-energy-systems-to-spread/2461743/Melanoma skin cancer cells may rewire their internal power systems to drive their spread to other parts of the body, a new study suggests. The research, led by investigators at Barts Cancer Institute, Queen Mary Unive
- Orlucent Receives FDA Breakthrough Device Designation for Handheld Mole Imaging Systemhttps://practicaldermatology.com/news/orlucent-receives-fda-breakthrough-device-designation-for-handheld-mole-imaging-system/2461733/The U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for Orlucent’s Skin Fluorescence Imaging System. The Orlucent system is a handheld point-of-care molecular-based imaging system designed to noninvasively identify and clinically assess the pres